Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dealmaker Breaks Down The Daiichi Sankyo-Ranbaxy Deal: PharmAsia News Spotlight

This article was originally published in PharmAsia News

Executive Summary

Japan health care reforms enacted in April aimed at increasing the use of generics helped set the stage for the watershed deal between Daiichi Sankyo and Ranbaxy, and will have major implications for Indian generics companies, according to Mehta Partners, the Indian firm that brokered the deal on behalf of Daiichi

You may also be interested in...



Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical

MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings

Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical

MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings

As Big Pharma Eye Big Buyouts In India, Merck KGaA Goes With Bangalore Genei To Sharpen Edge In Biologicals

MUMBAI - Away from the high decibel market speculation about moves made by Big Pharma to acquire large-sized companies in India, Darmstadt, Germany-headquartered Merck KGaA quietly picked up a little known molecular biology company called Bangalore Genei, which it claimed will help it "become one of the leading bioscience companies in India.

Related Content

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel